DIS3L2 Genotype

If a kidney cancer of young children (called Wilms tumor) has shown up in your family, or you are planning children and want to understand what you might pass on, this is one of the genes worth knowing about. An inherited change here quietly raises the risk of that cancer, usually with nothing else to signal it.

Most people who carry a single altered copy look and feel completely healthy, and so do many of their children. What this test gives you is information you can act on: a way to guide screening and family planning before anything happens.

What This Gene Carries Instructions For

DIS3L2 (short for DIS3-like exonuclease 2) is a gene that carries the recipe for a cleanup enzyme. That enzyme shreds worn-out or tagged genetic messages (molecules called RNA) floating inside the main body of the cell.

This enzyme is part of the cell's quality-control system, recognizing RNA that has been tagged for disposal and breaking it down. When the enzyme works normally, this housekeeping keeps growth and cell division orderly. When the gene is damaged, that cleanup falters, and in kidney tissue this appears to open the door to abnormal cell growth.

A Raised Risk of Childhood Kidney Cancer

Inheriting one altered copy of this gene (having a change in one of your two copies, known as being heterozygous) is a recognized predisposition to Wilms tumor. In the largest study to date, 34 children with Wilms tumor were found to carry a single altered inherited copy, including 4 from families with more than one affected relative. In a national study of 126 children with Wilms tumor, 5 carried a disabling change in one copy.

The cancers show up early, at a median age of 41 months (range 8 to 101 months) in the largest study. There is no recognizable outward appearance that flags these children, so a carrier is invisible without a gene test. That is the whole reason this test exists: the risk cannot be spotted by looking.

A tumor typically forms only when the one remaining working copy of the gene also fails inside kidney tissue, a change called a second hit. In one series, 19 of 20 tumors with genetic data carried this second hit, and in another 4 of 5 did. This is why a single inherited change is a predisposition and not a certainty.

Some early data suggest these tumors may behave more aggressively, with more spread to other sites, a more primitive tumor type under the microscope, and occasional disease in both kidneys. This finding is preliminary and comes from small numbers, so it should be held loosely until larger studies confirm it.

Perlman Syndrome

When both copies of this gene are knocked out (a state called biallelic loss, meaning an altered copy inherited from each parent), the result is Perlman syndrome. This is a severe inherited overgrowth disorder that is present at birth and carries a very high risk of Wilms tumor in infancy or early childhood.

This is where carrier couples matter most. Perlman syndrome follows a recessive pattern, which means a child develops it only if both parents pass on an altered copy. Two healthy carriers can have an affected child even though neither parent has any signs of disease.

Exon 9, a Spot Standard Tests Can Miss

The most common change in this gene is not a single misspelled letter but a missing chunk, a deletion of a segment called exon 9. In the largest Wilms tumor study, this deletion accounted for 28 of the 34 carriers, with other types of change making up the rest.

Because this is a missing piece of DNA rather than a typo, ordinary gene sequencing that reads letters one by one can slide right past it. Detecting it takes a method that counts how many copies of each segment are present (copy-number analysis). A test that is not designed to catch deletions can return a falsely reassuring result.

This deletion is not a single ancestral variant handed down through one family line. Unrelated carriers do not share the surrounding DNA pattern, which points to the same deletion arising independently over and over, likely because repetitive stretches of DNA that flank this region tend to swap and recombine. The practical takeaway is simple: make sure any test you order looks for deletions, not just letter changes.

A Result You Only Need Once

Your genotype is fixed. The result would read the same if you tested it next year or in thirty years, so there is no trend to track and no reason to repeat the gene test itself. Its value is not in retesting but in what you do with it over the years that follow.

For a carrier with young children, that means the companion to this one-time result is ongoing imaging of the kidneys. Regular abdominal ultrasound during the early childhood window is the standard way to catch a Wilms tumor early. Published surveillance guidelines for children at increased risk generally recommend a kidney ultrasound every 3 months until about age 7, but the exact plan should be set with a clinical geneticist or pediatric oncologist based on the specific variant and family situation.

What to Do With an Abnormal Result

A positive result is a starting point for a workup, not an endpoint. If the finding came from a chip or panel rather than direct sequencing, confirming it with a second method is reasonable before major decisions follow. A clinical geneticist should help interpret exactly what your specific change means, since risk depends heavily on variant type and family history.

Two combinations of findings drive the biggest decisions. A single altered copy in someone with a young child points toward a conversation about kidney imaging surveillance for that child. Two carriers in a couple planning a family points toward reproductive counseling, because that is the setup that can produce a child with Perlman syndrome.

Because this change can run silently through a family, a positive result is also a prompt to talk with biological relatives. Siblings, children, and parents each have a meaningful chance of carrying the same variant, and testing them can redirect screening for the people who need it.

When a Result Can Mislead

• What the panel covers: the test only detects the specific changes it was built to find, so a negative result does not rule out every rare change in this gene. Above all, the test must be able to detect deletions, or it can miss the common exon 9 loss entirely.
• Your ancestry: how common a given change is, and sometimes what it means, can differ between populations, so results are best interpreted in the context of your genetic background.
• A change of unknown meaning: an assay may report a variant that has never been clearly linked to disease, labeled as uncertain. This is not the same as a known harmful change and should not trigger drastic action on its own.
• Consumer versus clinical tests: a direct-to-consumer report that touched this region may only read single letters and can miss deletions, so a clinical-grade test is what settles the question.